E157Q integrase strand-transfer inhibitor substitution in patients with acute/recent HIV infection.

08:00 EDT 6th May 2019 | BioPortfolio

Summary of "E157Q integrase strand-transfer inhibitor substitution in patients with acute/recent HIV infection."

Integrase strand-transfer inhibitor (InSTI)-based regimens are the preferred combinations for naïve HIV-infected individuals. Polymorphic substitutions that reduce InSTIs activity have been described, with E157Q being one of the most frequently found. This study aimed to evaluate the prevalence of E157Q substitution in newly diagnosed acute/recent HIV cases and the presence of transmission clusters.


Journal Details

This article was published in the following journal.

Name: AIDS (London, England)
ISSN: 1473-5571


DeepDyve research library

PubMed Articles [31194 Associated PubMed Articles listed on BioPortfolio]

Durability of first-line regimens including integrase strand transfer inhibitors (INSTIs): data from a real-life setting.

To evaluate the durability of three integrase strand transfer inhibitors (INSTIs) and two NRTIs in ART-naive individuals.

Integrase inhibitor-based regimens result in more rapid virologic suppression rates among treatment-naïve human immunodeficiency virus-infected patients compared to non-nucleoside and protease inhibitor-based regimens in a real-world clinical setting: A retrospective cohort study.

The integrase strand transfer inhibitor (INSTI) class of antiretroviral therapy (ART) may result in faster time to virologic suppression compared with regimens that contain protease inhibitors (PIs) o...

Effectiveness of integrase strand transfer inhibitors among treatment-experienced patients in a clinical setting.

Characterize virologic and immunologic outcomes of INSTI-based antiretroviral therapy (ART) in experienced patients with and without virologic failure.

Is there a safety signal for dolutegravir and integrase inhibitors during pregnancy?

Dolutegravir, an integrase strand transfer inhibitor (InSTI) is a major antiretroviral agent for HIV infection. Its use is promising, especially in low and middle-income countries, because of a high r...

Assessment of antiretroviral third agent virologic durability after initiation of first antiretroviral regimen.

Information on the virologic durability of modern antiretroviral regimens is important to clinicians. We aimed to describe virologic durability of first-line integrase strand transfer inhibitor (INSTI...

Clinical Trials [3702 Associated Clinical Trials listed on BioPortfolio]

AMICI Study: A Study of Fuzeon (Enfuvirtide) With an Integrase Inhibitor Plus Optimized Background in Treatment-Experienced HIV-1 Infected Patients.

This 2 arm study will evaluate the efficacy and safety of Fuzeon with an integrase inhibitor in an expanded access program plus optimized background in HIV-1 infected patients naive to Fuz...

A Clinical Research Study for Assessing the Effectiveness of the New Integrase Inhibitor GSK1349572 in HIV-infected Persons With Prior Antiretroviral Treatment and Resistance to Raltegravir

Integrase is an enzyme produced by HIV so that the virus can multiply in the human body. GSK1349572 is a new drug in the integrase inhibitor class that prevents the enzyme from working pro...

Immune Responses in Patients Treated With Raltegravir

Hypothesis: Treatment with raltegravir does not alter V(D)J recombination or immune responses to neoantigens. A process known as V(D)J recombination is essential for developing lymphocyte...

Phase IIa Dose-ranging Study of GSK1349572 in HIV-1 Infected Adults

GSK1349572 is an integrase inhibitor that will be evaluated for the treatment of HIV infection. This phase IIa, multicenter, randomized, parallel, double-blind, dose ranging, placebo-contr...

Safety and Effectiveness of Zintevir (AR177) Given to HIV-Infected Patients

The purpose of this study is to see if it is safe and effective to give zintevir (AR177) to asymptomatic (no symptoms) HIV-infected patients. Zintevir belongs to a new class of anti-HIV d...

Medical and Biotech [MESH] Definitions

Compounds which inhibit or antagonize biosynthesis or actions of integrase.

Enzyme of the HUMAN IMMUNODEFICIENCY VIRUS that is required to integrate viral DNA into cellular DNA in the nucleus of a host cell. HIV integrase is a DNA nucleotidyltransferase encoded by the pol gene.

A pyrrolidinone derivative and HIV INTEGRASE INHIBITOR that is used in combination with other ANTI-HIV AGENTS for the treatment of HIV INFECTION.

Inhibitors of HIV INTEGRASE, an enzyme required for integration of viral DNA into cellular DNA.

Interfacility or intrahospital transfer of patients. Intrahospital transfer is usually to obtain a specific kind of care and interfacility transfer is usually for economic reasons as well as type of care provided.

Quick Search


DeepDyve research library

Relevant Topics

AIDS; Acquired Immune Deficiency Syndrome. HIV; Human Immunodeficiency Virus HIV infection causes AIDS. HIV infection also causes the production of anti-HIV antibodies, which forms the test for HIV in patients. People who have the HIV antibodies are ...

Antiretroviral Therapy Clostridium Difficile Ebola HIV & AIDS Infectious Diseases Influenza Malaria Measles Sepsis Swine Flu Tropical Medicine Tuberculosis Infectious diseases are caused by pathogenic...

Searches Linking to this Article